Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.
IMRN stock price ended at $0.94 on 月曜日, after dropping 4.08%
On the latest trading day Jan 26, 2026, the stock price of IMRN fell by 4.08%, dropping from $0.99 to $0.94. During the session, the stock saw a volatility of 6.38%, with prices oscillating between a daily low of $0.94 and a high of $1.00. On the latest trading day, the trading volume for IMRN rose by 1.1K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 17.4K shares were traded, with a market value of approximately $7.5M.